Synapse - A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies

A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies Meeting Abstract

Authors:	Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; Hensley, M. L.; Zamarin, D.; Konner, J. A.; Charen, A. S.; Cadoo, K. A.; Spriggs, D. R.; Iyer, G.; Aghajanian, C.
Abstract Title:	A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
Meeting Title:	53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	15 Suppl.
Meeting Dates:	2017 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-05-20
Start Page:	313s
Language:	English
ACCESSION:	WOS:000411931704087
DOI:	10.1200/JCO.2017.35.15_suppl.TPS5610
PROVIDER:	wos
Notes:	Meeting Abstract: TPS5610 -- Source: Wos